CLOT RETRIEVAL DEVICE MARKET

INTRODUCTION

Stroke is the second biggest cause of mortality in the globe and Europe. Even with the gold standard medical treatment for acute ischemic stroke, intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA), the death rate remains unchanged.

Because of the small sample size, intra-arterial (IA) thrombolysis treatment did not provide meaningful outcomes and was not authorized by the US Food and Drug Administration (FDA).

This prompted scientists and engineers to create endovascular clot extraction devices for mechanically recanalizing blocked arteries in stroke patients.

Despite the failure of the early designs of clot retrieval devices, attempts to develop these devices continue. Clot retrieval devices, together with IV rt-PA, were recently authorized by the FDA as first-line therapy.

This article provides an in-depth review of various clot retrieval devices, including MERCI (the first), the Penumbra Aspiration System, Embow Trap, stent retrievers, and the path forward with the new FDA clearance of the devices as first-line treatment for acute ischemic stroke, in addition to IV rt-PA. A comparison of clot retrieval devices to gold standard therapy is also included in the evaluation.

Cerebrovascular disease is one of the world's major causes of morbidity and death. Stroke is the sixth greatest cause of mortality in the United States, killing thousands of individuals each year.

It is the world's second biggest cause of death. Stroke was responsible for one out of every ten fatalities. According to the National Health and Nutrition Examination Survey (NHANES) from, about a million people.

Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the current gold standard medical treatment for acute ischemic stroke. When given within a few hours after the commencement of ischemic stroke symptoms, it may raise the odds of a favorable neurological or functional result with no substantial impairment months later.

However, it does not reduce mortality, and it is questionable if it fulfills the goal of full recanalization of blocked arteries, particularly big ones. Although IV rt-PA therapy is beneficial, the narrow therapeutic window, potential serious complication of symptomatic intracranial hemorrhage, and low rate of recanalization of occluded arteries have prompted clinicians and scientists to seek out other effective and novel therapies for ischemic stroke.

An intra-arterial (IA) thrombolysis approach was evaluated utilizing several thrombolytic drugs such as rt-PA, urokinase (UK), and recombinant pro-urokinase (r-pro-UK) in order to accomplish full arterial recanalization and widen the therapeutic window. In theory, IA thrombolysis offers the benefit of attaining a better recanalization rate while using fewer fibrinolytic drugs. 

In one of the main clinical trials, Intra-arterial Procure kinase for Acute Ischemic Stroke (PROACT II), treatment with r-pro-UK resulted in favorable clinical results in patients with MCA occlusion.

The median time to therapy was h, and recanalization was accomplished in the patients, whereas those treated with r-pro-UK had a modified Rankin Scale (MRS) score of or less.

They have seen significant breakthroughs in the development of numerous medical devices and their transcatheter delivery methods throughout the years.

This is especially true in the field of cardiovascular disorders, where directing the catheter can become technically difficult and necessitates constant system development to obtain results with minimal procedure-related problems. 

With emerging transcatheter multimodal drug, patch, and stent delivery systems for various functional and structural cardiovascular diseases such as myocardial infarction, intracardiac septal defects, and peripheral vascular diseases, They have learned that regulatory hurdles must be overcome in addition to technical complexities.

This was also shown in the field of acute ischemic stroke, where the FDA's rejection of endovascular IA thrombolytic stroke treatment cleared the path for its development and advancement.

The three prospective, multicenter randomized controlled trials that found no benefit from endovascular mechanical thrombectomy when compared to the gold standard IV rt-PA were the Interventional Management of Stroke (IMS) III, SYNTHESIS Expansion, and The Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE).

Neuro interventionalists expressed concerns about several features of the research designs of these failed endovascular stroke studies.

 The failure of these experiments was ascribed to two key reasons: (1) Except in MR RESCUE, large artery occlusion was not commonly diagnosed utilizing imaging modalities such as computed tomography angiography (CTA) or magnetic resonance angiography (MRA); (2) New generation clot retrieval devices such as stent retrievers were not widely employed in these studies.

CLOT RETRIEVAL DEVICE MARKET SIZE AND FORECAST

The Global Clot Retrieval Device Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

CLOT RETRIEVAL DEVICE MARKET NEW PRODUCT LAUNCH

Imperative Care, Inc. today announced the release of its Zoom POD Aspiration Tubing, the company's latest advancement in stroke care. The Zoom POD is the latest addition to Imperative Care's Zoom Stroke Solution, which comprises the Zoom 88 Large Distal Platform for neurovascular access, four Zoom Aspiration Catheters in varying diameters, and the Zoom Pump with accessories.

The Zoom POD is the first and only sterile field clot filtration device, allowing for speedier clot collecting during important mechanical thrombectomy treatments for patients with ischemic stroke.

The Zoom POD is built into the aspiration tube, reducing the distance between aspiration and filtration while retaining full aspiration strength. The physician can see the clot instantly since he is in the sterile field.

The Zoom Stroke Solution is a full stroke solution that provides patients with acute ischemic stroke with rapid and efficient clot removal from access to reperfusion. The Zoom 88 Large Distal Platform for neurovascular access, four vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD, and accessories are all included in the system.

All Zoom catheters have the TRX Tip, which gives more clot contact area at the catheter's tip and allows for smooth tracking through difficult vasculature.

THIS CLOT RETRIEVAL DEVICE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many  Clot Retrieval Devices   are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Clot Retrieval Device   and key vendor selection criteria
3. Where is the Clot Retrieval Device  manufactured? What is the average margin per unit?
4. Market share of Global Clot Retrieval Device   market  manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Clot Retrieval Device   in-house
6. 5 key predictions for next 5 years in Global Clot Retrieval Device   market
7. Average B-2-B  Clot Retrieval Device market price in all segments
8. Latest trends in  Clot Retrieval Device market, by every market segment
9. The market size (both volume and value) of the  Clot Retrieval Device   market in 2024-2030 and every year in between?
10. Production breakup of  Clot Retrieval Device   market, by suppliers and their OEM relationship